Understanding ITGB3: Potential Drug Target and Biomarker (G3690)

Target Name: ITGB3

NCBI ID: G3690

ITGB3

Understanding ITGB3: Potential Drug Target and Biomarker

ITGB3, also known as integrin beta 3, is a protein that is expressed in the cells that make up the immune system, including blood cells, tissue cells, and cancer cells. It is a key regulator of the immune response and has been linked to the development and progression of many diseases, including cancer.

Recent studies have identified ITGB3 as a potential drug target and biomarker for a variety of diseases, including cancer, autoimmune disorders, and inflammatory diseases. This is because ITGB3 has been shown to play a role in the regulation of immune cell function and has been shown to interact with a variety of signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT.

One of the key challenges in studying ITGB3 is its complex structure and the fact that it is expressed in a variety of cell types. This makes it difficult to study and understand its functions fully. However, researchers have been able to identify several key functions of ITGB3, including its role in cell adhesion, migration, and the regulation of inflammation.

One of the most promising aspects of ITGB3 is its potential as a drug target. Researchers have identified several potential drug candidates that target ITGB3, including small molecules, antibodies, and peptideides. These drugs have been shown to have a variety of biological effects, including inhibiting the activity of ITGB3, modulating its expression, and triggering an immune response.

In addition to its potential as a drug target, ITGB3 has also been identified as a potential biomarker for a variety of diseases. Its expression has been shown to be associated with the development of cancer, autoimmune disorders, and other diseases. Researchers have also been able to use ITGB3 as a marker to track the progress of disease and to identify potential therapeutic targets.

Overall, ITGB3 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its functions and to develop safe and effective drugs and treatments based on its properties.

Protein Name: Integrin Subunit Beta 3

Functions: Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. Fibrinogen binding enhances SELP expression in activated platelets (By similarity). ITGAV:ITGB3 binds to fractalkine (CX3CL1) and acts as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415, PubMed:24789099). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887). In brain, plays a role in synaptic transmission and plasticity. Involved in the regulation of the serotonin neurotransmission, is required to localize to specific compartments within the synapse the serotonin receptor SLC6A4 and for an appropriate reuptake of serotonin. Controls excitatory synaptic strength by regulating GRIA2-containing AMPAR endocytosis, which affects AMPAR abundance and composition (By similarity). ITGAV:ITGB3 act as a receptor for CD40LG (PubMed:31331973)

The "ITGB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets